You are right, licensing deals might very well be broken down by World Region. Makes a lot of sense. I was thinking along the lines of Biogen just licensing for MS,but World Wide as they would be the ones developing A2-73 for that indication as Anavex has just pre-clinical work on MS indication.
I do not mean to imply that I think MS only is more or less likely than any other permutation of possible deals just that MS is what they are testing for and it is the most conservative prediction of possible deals.
But I would expect if they did license A2-73 for MS only it would be World-wide as they are in a position to develop it for World-wide application and distribution.
NA=North America Duh! Ha ha! I think I need stronger coffee to cut through the weekend fog.
News 
Market Data 
Discover 
